glucagon has been researched along with oxybutynin in 5 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (oxybutynin) | Trials (oxybutynin) | Recent Studies (post-2010) (oxybutynin) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 2,607 | 619 | 1,670 |
| Protein | Taxonomy | glucagon (IC50) | oxybutynin (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.5951 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.027 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.002 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0032 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0035 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0027 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.5951 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.6 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.4288 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.792 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.0855 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0242 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Branigan, D; Castle, JR; Cummins, M; Newswanger, B; Prestrelski, S; Shi, L; Strange, P; Youssef, JE | 1 |
| GhavamiNejad, A; Giacca, A; Lam, L; Li, J; Lu, B; Wu, XY; Zhou, L | 1 |
| Buse, JB; Chen, G; Gu, Z; Kahkoska, AR; Li, H; Miedema, JR; Wang, J; Wang, Z; Wen, D; Wu, V; Yu, J; Zeng, Y | 1 |
| GhavamiNejad, A; Giacca, A; Liu, JF; Lu, B; Mirzaie, S; Pereira, S; Samarikhalaj, M; Wu, XY; Zhou, L | 1 |
| Fu, R; Gu, Z; Han, X; Li, S; Wang, Z; Wen, D; Wu, Y | 1 |
1 trial(s) available for glucagon and oxybutynin
| Article | Year |
|---|---|
Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon Versus Lyophilized Glucagon in Type 1 Diabetes Subjects.
Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Gastrointestinal Agents; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Male; Middle Aged; Transdermal Patch; Young Adult | 2016 |
4 other study(ies) available for glucagon and oxybutynin
| Article | Year |
|---|---|
Glucose-Responsive Composite Microneedle Patch for Hypoglycemia-Triggered Delivery of Native Glucagon.
Topics: Animals; Blood Glucose; Cross-Linking Reagents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Liberation; Gels; Glucagon; Humans; Hyaluronic Acid; Hypoglycemia; Hypoglycemic Agents; Insulin; Methacrylates; Needles; Photochemical Processes; Polymerization; Rats; Transdermal Patch | 2019 |
Dual self-regulated delivery of insulin and glucagon by a hybrid patch.
Topics: Animals; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Combinations; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Overdose; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Mice; Polymerization; Solubility; Streptozocin; Transdermal Patch | 2020 |
Transdermal delivery of a somatostatin receptor type 2 antagonist using microneedle patch technology for hypoglycemia prevention.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Delivery Systems; Glucagon; Humans; Hypoglycemia; Insulin; Needles; Polymers; Rats; Receptors, Somatostatin; Technology; Transdermal Patch | 2022 |
Shrinking Fabrication of a Glucose-Responsive Glucagon Microneedle Patch.
Topics: Animals; Biocompatible Materials; Diabetes Mellitus; Glucagon; Glucose; Hypoglycemia; Insulin; Mice; Transdermal Patch | 2022 |